VSTM, US92337C2035

Verastem prices USD 250 million offering of Verastem stock

Published on 10/25/2026 at 13:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 14 financing covered 30.94 million shares at USD 8.00. For Verastem stock, results are set for November 5, 2026.

Clinical data and reporting date

Verastem priced USD 250.00 million of financing on October 14, 2026.
VS-7375 produced a 50.00 percent confirmed response rate in second-line pancreatic cancer on October 14, 2026.
Verastem will report third-quarter 2026 results on November 5, 2026.

VSTM, US92337C2035, Illustration mit AI erstellt.

Verastem (ISIN US92337C2035) priced an offering expected to raise USD 250.00 million on October 14, 2026, giving its cancer pipeline additional funding. According to Verastem Oncology, the financing was paired with clinical data and a planned leadership transition.

Funding supports VS-7375

The company priced 30,937,500 common shares at USD 8.00 each, plus pre-funded warrants for up to 312,503 shares at USD 7.9999. Gross proceeds are expected to reach USD 250.00 million before discounts and expenses, with the proceeds directed toward clinical development, working capital and general corporate purposes, according to Verastem Oncology.

What does the cancer data show?

The main operating signal came from VS-7375, an investigational oral KRAS G12D inhibitor. In data available on October 7, 2026, the treatment produced a 50.00 percent confirmed objective response rate in second-line pancreatic cancer, equal to 4 of 8 patients, and a 41.00 percent rate in the broader second-line-or-later group, equal to 9 of 22 patients. The figures were reported by Verastem Oncology.

Three October milestones

On October 14, 2026, the VS-7375 update recorded a 50.00 percent response rate in second-line pancreatic cancer. On October 14, 2026, Verastem named Michael P. Bailey president and chief executive officer effective January 1, 2027, according to Verastem Oncology. On October 14, 2026, the company priced the USD 250.00 million offering.

Two dates shape the next phase

Verastem is scheduled to report third-quarter 2026 financial results on November 5, 2026, at 4:30 p.m. ET, according to Morningstar. The leadership transition is scheduled for January 1, 2027, while Bailey is expected to guide the company through commercial execution and further VS-7375 development.

Nasdaq value and risk

The Nasdaq quote was last at USD 10.04 on October 23, 2026 at 4:00 p.m. ET. The USD 250.00 million financing expands resources, but the issuance of 30,937,500 shares also creates dilution risk for existing holders.

The further course of trading is shown by the continuously updated real-time quote of Verastem stock.